27711225|t|Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone
27711225|a|Benign human prostate tubule-initiating cells (TIC) and aggressive prostate cancer display common traits, including tolerance of low androgen levels, resistance to apoptosis, and microenvironment interactions that drive epithelial budding and outgrowth. TIC can be distinguished from epithelial and stromal cells that comprise prostate tissue via cell sorting based upon Epcam, CD44, and CD49f antigenic profiles. Fetal prostate epithelial cells (FC) possess a similar antigenic profile to adult TIC and are capable of inducing tubule formation. To identify the TIC niche in human prostate tissue, differential keratin (KRT) expression was evaluated. Gene expression data generated from Affymetrix Gene Chip human U133 Plus 2.0 array of sorted adult and fetal epithelial cells revealed KRT13 to be significantly enriched in FC and TIC compared to basal cells (BC) and luminal cells (LC) (p<0.001). Enriched KRT13 expression was confirmed by RT-PCR and cytospin immunostaining. Immunohistochemical analysis of KRT13 expression revealed rare KRT13+ epithelia throughout prostatic ducts / acini in adult tissue specimens and differentiated tubules in 24- week recombinant grafts, In contrast, abundant KRT13 expression was observed in developing ducts / acini in fetal prostate and cord-like structures composing 8- week recombinant grafts. Immunostaining of a prostate tissue microarray revealed KRT13+ tumor foci in approximately 9% of cases, and this subset displayed significantly shorter time to recurrence (p = 0.031), metastases (p = 0.032), and decreased overall survival (p = 0.004). Diagnostic prostate needle biopsies (PNBX) from untreated patients with concurrent bone metastases (clinical stage M1) displayed KRT13+ tumor foci, as did bone metastatic foci. The expression profile of KRT13 in benign fetal and adult prostate tissue and in recombinant grafts, as well as the frequency of KRT13 expression in primary and metastatic prostate cancer indicates that it may be a marker of a stem/progenitor-like cell state that is co-opted in aggressive tumor cells. KRT13 is enriched in benign stem-like cells that display androgen - resistance, apoptosis - resistance, and branching morphogenesis properties. Collectively our data demonstrate that KRT13 expression is associated with poor prognosis at multiple stages of disease progression and may represent an important biomarker of adverse outcome in patients with prostate cancer.
27711225	0	10	Keratin 13	T116,T123	C0010804
27711225	26	34	Prostate	T023	C0033572
27711225	35	58	Tubule-Initiating Cells	T025	C0007634
27711225	67	75	Identify	T080	C0205396
27711225	76	99	Primary Prostate Tumors	T191	C0033578
27711225	105	116	Metastasize	T191	C0027627
27711225	124	128	Bone	T023	C0262950
27711225	136	141	human	T016	C0086418
27711225	142	150	prostate	T023	C0033572
27711225	151	174	tubule-initiating cells	T025	C0007634
27711225	176	179	TIC	T025	C0007634
27711225	185	195	aggressive	T079	C0580822
27711225	196	211	prostate cancer	T191	C0600139
27711225	212	219	display	T169	C0870432
27711225	227	233	traits	T032	C0599883
27711225	245	254	tolerance	T080	C1704410
27711225	258	277	low androgen levels	T033	C3203518
27711225	279	289	resistance	T169	C4281815
27711225	293	302	apoptosis	T043	C0162638
27711225	308	337	microenvironment interactions	T043	C0007613
27711225	349	367	epithelial budding	T043	C1155616
27711225	372	381	outgrowth	T043	C0007595
27711225	383	386	TIC	T025	C0007634
27711225	413	423	epithelial	T025	C0014597
27711225	428	441	stromal cells	T025	C0162597
27711225	447	455	comprise	T052	C2700400
27711225	456	471	prostate tissue	T024	C0227964
27711225	476	488	cell sorting	T059	C0007616
27711225	500	505	Epcam	T028	C0812305
27711225	507	511	CD44	T028	C1332712
27711225	517	522	CD49f	T028	C1442491
27711225	543	574	Fetal prostate epithelial cells	T025	C0014597
27711225	576	578	FC	T025	C0014597
27711225	598	607	antigenic	T129	C0003320
27711225	619	624	adult	T100	C0001675
27711225	625	628	TIC	T025	C0007634
27711225	648	656	inducing	T169	C0205263
27711225	657	673	tubule formation	T033	C1718420
27711225	678	686	identify	T080	C0205396
27711225	691	694	TIC	T025	C0007634
27711225	704	709	human	T016	C0086418
27711225	710	725	prostate tissue	T024	C0227964
27711225	740	747	keratin	T116,T123	C0010804
27711225	749	752	KRT	T116,T123	C0010804
27711225	754	764	expression	T045	C1171362
27711225	769	778	evaluated	T058	C0220825
27711225	780	795	Gene expression	T045	C0017262
27711225	796	800	data	T078	C1511726
27711225	816	862	Affymetrix Gene Chip human U133 Plus 2.0 array	T063	C4284067
27711225	866	872	sorted	T052	C1947906
27711225	873	878	adult	T100	C0001675
27711225	883	888	fetal	T169	C0521457
27711225	889	905	epithelial cells	T025	C0014597
27711225	906	914	revealed	T080	C0443289
27711225	915	920	KRT13	T116,T123	C1673263
27711225	927	949	significantly enriched	T081	C4055637
27711225	953	955	FC	T025	C0014597
27711225	960	963	TIC	T025	C0007634
27711225	976	987	basal cells	T025	C0596155
27711225	989	991	BC	T025	C0596155
27711225	997	1010	luminal cells	T025	C0007634
27711225	1012	1014	LC	T025	C0007634
27711225	1036	1041	KRT13	T116,T123	C1673263
27711225	1042	1052	expression	T045	C1171362
27711225	1057	1069	confirmed by	T080	C0521093
27711225	1070	1076	RT-PCR	T063	C0599161
27711225	1081	1104	cytospin immunostaining	T059	C0016318
27711225	1106	1134	Immunohistochemical analysis	T059	C1441616
27711225	1138	1143	KRT13	T116,T123	C1673263
27711225	1144	1154	expression	T045	C1171362
27711225	1155	1163	revealed	T080	C0443289
27711225	1169	1175	KRT13+	T116,T123	C1673263
27711225	1197	1212	prostatic ducts	T023	C0227965
27711225	1215	1220	acini	T023	C0229962
27711225	1224	1229	adult	T100	C0001675
27711225	1230	1246	tissue specimens	T024	C1292533
27711225	1251	1265	differentiated	T080	C0205616
27711225	1266	1273	tubules	T026	C3893601
27711225	1281	1285	week	T079	C0439230
27711225	1286	1304	recombinant grafts	T001	C1514798
27711225	1328	1333	KRT13	T116,T123	C1673263
27711225	1334	1344	expression	T045	C1171362
27711225	1349	1357	observed	T169	C1441672
27711225	1372	1377	ducts	T023	C0227965
27711225	1380	1385	acini	T023	C0229962
27711225	1389	1403	fetal prostate	T023	C0033572
27711225	1408	1428	cord-like structures	T082	C0678594
27711225	1442	1446	week	T079	C0439230
27711225	1447	1465	recombinant grafts	T001	C1514798
27711225	1467	1481	Immunostaining	T059	C1508788
27711225	1487	1495	prostate	T023	C0033572
27711225	1496	1513	tissue microarray	T075	C1519522
27711225	1514	1522	revealed	T080	C0443289
27711225	1523	1535	KRT13+ tumor	T191	C0027651
27711225	1536	1540	foci	T082	C0205234
27711225	1564	1569	cases	T169	C0868928
27711225	1580	1586	subset	T185	C1515021
27711225	1587	1596	displayed	T169	C0870432
27711225	1611	1623	shorter time	T079	C0040223
27711225	1627	1637	recurrence	T067	C0034897
27711225	1651	1661	metastases	T191	C0027627
27711225	1679	1688	decreased	T081	C0205216
27711225	1689	1705	overall survival	T081	C4086681
27711225	1719	1754	Diagnostic prostate needle biopsies	T060	C3867555
27711225	1756	1760	PNBX	T060	C3867555
27711225	1767	1776	untreated	T033	C0332155
27711225	1777	1785	patients	T101	C0030705
27711225	1791	1801	concurrent	T079	C0205420
27711225	1802	1817	bone metastases	T191	C0153690
27711225	1819	1836	clinical stage M1	T033	C0441971
27711225	1848	1854	KRT13+	T116,T123	C1673263
27711225	1855	1860	tumor	T191	C0027651
27711225	1861	1865	foci	T082	C0205234
27711225	1874	1878	bone	T023	C0262950
27711225	1879	1889	metastatic	T191	C0027627
27711225	1890	1894	foci	T082	C0205234
27711225	1900	1918	expression profile	T034	C3463810
27711225	1922	1927	KRT13	T116,T123	C1673263
27711225	1931	1943	benign fetal	T169	C0521457
27711225	1948	1953	adult	T100	C0001675
27711225	1954	1969	prostate tissue	T024	C0227964
27711225	1977	1995	recombinant grafts	T001	C1514798
27711225	2012	2021	frequency	T079	C0439603
27711225	2025	2030	KRT13	T116,T123	C1673263
27711225	2031	2041	expression	T045	C1171362
27711225	2057	2083	metastatic prostate cancer	T191	C0936223
27711225	2084	2093	indicates	T078	C3146298
27711225	2111	2117	marker	T201	C0005516
27711225	2123	2143	stem/progenitor-like	T025	C0038250
27711225	2144	2148	cell	T025	C0007634
27711225	2175	2191	aggressive tumor	T191	C2945759
27711225	2192	2197	cells	T025	C0007634
27711225	2199	2204	KRT13	T116,T123	C1673263
27711225	2220	2226	benign	T080	C0205183
27711225	2227	2236	stem-like	T025	C0038250
27711225	2237	2242	cells	T025	C0007634
27711225	2248	2255	display	T169	C0870432
27711225	2256	2264	androgen	T121,T125	C0002844
27711225	2267	2277	resistance	T169	C4281815
27711225	2279	2288	apoptosis	T043	C0162638
27711225	2291	2301	resistance	T169	C4281815
27711225	2307	2330	branching morphogenesis	T040	C1622374
27711225	2331	2341	properties	T080	C0871161
27711225	2360	2364	data	T078	C1511726
27711225	2382	2387	KRT13	T116,T123	C1673263
27711225	2388	2398	expression	T045	C1171362
27711225	2402	2417	associated with	T080	C0332281
27711225	2423	2432	prognosis	T201	C3854082
27711225	2436	2451	multiple stages	T079	C1306673
27711225	2455	2474	disease progression	T046	C0242656
27711225	2483	2492	represent	T052	C1882932
27711225	2506	2515	biomarker	T201	C0005516
27711225	2538	2546	patients	T101	C0030705
27711225	2552	2567	prostate cancer	T191	C0600139